AI-Aided Analysis Technology Platform

Q: How do you validate the AI-predicted neoantigens?

We offer a range of preclinical in vitro immunogenicity services, such as ELISpot, flow cytometry, and in vivo efficacy studies in animal models to confirm that the AI-predicted targets elicit the expected anti-tumor immune responses.

Empowering the next generation of precision immunotherapy through deep learning-driven computational pipelines. We provide end-to-end preclinical analysis services to transform raw sequencing data into high-confidence, immunogenic neoantigen candidates with unprecedented speed and accuracy.

Overview: Navigating the Complexity of the Tumor Mutanome with AI

Overcoming Conventional Bottlenecks in Preclinical Neoantigen Selection

The success of personalized cancer immunotherapy hinges on the identification of neoantigens—unique peptides derived from tumor-specific mutations. Traditional prediction methods often suffer from high false-positive rates and a limited ability to account for the biological nuances of antigen processing and TCR recognition. Creative Biolabs has developed an AI-Aided Analysis Technology Platform designed specifically for preclinical research teams.

By leveraging advanced neural networks and structural modeling, our platform evaluates millions of potential candidates to pinpoint those most likely to trigger a robust immune response in vivo. Our goal is to de-risk your vaccine development by ensuring only the most potent epitopes advance to the validation phase.

Core Objectives of Our AI-Aided Platform:
High-accuracy MHC binding and stability prediction.
In-depth evaluation of proteasomal cleavage and TAP transport.
Modeling of the TCR-pMHC interaction to assess actual immunogenicity potential.
Rapid prioritization of candidates for integrated preclinical vaccine testing.

By moving beyond simple sequence alignment to a "multidimensional AI filter," we address the high failure rate of neoantigens that look good on paper but fail to elicit responses in in vitro cell assays or in vivo models. Our services are tailored for researchers working on advanced mRNA, DNA, or peptide-based vaccine platforms.

AI-Aided Analysis Services for Preclinical Immunotherapy Development

Deep Learning-Enhanced Mutation Mining

We utilize high-precision neural networks to integrate Whole Exome (WES) and RNA-Seq data. Our platform excels in identifying non-canonical neoantigens—such as those from alternative splicing or gene fusions—while deploying Bayesian filters to eliminate sequencing artifacts and false positives at the source.

Multi-Omic Integration Rare Variant Detection Noise Reduction

MHC-Peptide Presentation Simulation

Going beyond static binding affinity, our AI models the kinetic lifecycle of antigen presentation. We simulate proteasomal cleavage patterns and TAP transporter efficiency to predict which neoepitopes actually reach the cell surface, ensuring candidates possess high structural stability and presentation density.

Cleavage Site Prediction pMHC Kinetics Pathway Simulation

Advanced TCR-pMHC Recognition Profiling

Our platform assesses "functional immunogenicity" by modeling the structural interface between T-cell receptors and the pMHC complex. By evaluating sequence similarity to known pathogens and cross-reactivity with self-peptides, we prioritize antigens most likely to trigger a robust cytotoxic T-cell response.

TCR Contact Modeling Self-Similarity Filter Potency Scoring

AI-Aided Preclinical Strategy Development

We translate complex computational data into optimized experimental roadmaps. This service includes selecting the best research models (syngeneic mice, PDX) and designing in vitro immunogenicity assays (ELISpot, flow cytometry) that align perfectly with the AI-predicted strengths of your top candidates.

Study Design Support Model Selection AI End-to-End Interpretation

The AI-Aided Analysis Workflow: From Data to Discovery

AI-aided analysis workflow for neoantigen prediction

Step 1 — Raw Sequence Data Analysis

Clients provide FASTQ or VCF files from tumor and healthy tissues for initial processing and quality control.

Step 2 — AI-Corrected Mutation Discovery

Our neural networks filter out background noise and identify tumor-specific somatic variants, insertions, and deletions.

Step 3 — Antigen Processing Simulation

Machine learning models predict proteasomal cleavage patterns and the efficiency of the TAP (Transporter associated with Antigen Processing) system.

Step 4 — MHC Binding & Stability Assessment

High-precision AI-aided models simulate the binding affinity and dissociation rates for the client's specific HLA profile.

Step 5 — Deep Learning Immunogenicity Scoring

Multi-parameter algorithms evaluate TCR recognition probability, self-similarity, and cytokine induction potential.

Step 6 — Integrated Validation Guidance

Top candidates are selected for in vitro immunogenicity assays and preclinical in vivo efficacy tests in research models.

Service Phase	Traditional Challenges	Our AI-Aided Advantages
Data Mining	High false-positive mutation calls	Deep learning-driven noise reduction and variant verification
Epitope Mapping	Over-reliance on simple binding affinity	Holistic processing pathway simulation via AI models
Immunogenicity	Uncertain T-cell activation potential	TCR recognition propensity and self-tolerance modeling
Turnaround Time	Months of manual selection and testing	Automated high-speed screening within days
Preclinical Fit	Disconnected sequence-to-study design	AI-guided study design for in vivo proof-of-concept

Unique Technology Platforms: AI-Driven Insights

Multi-Omic Neoantigen Discovery System

An integrative computational framework that harmonizes genomic, transcriptomic, and proteomic datasets to prioritize highly immunogenic neoepitopes for preclinical evaluation.

TCR-pMHC Interactive Structural Modeler

Advanced simulation of the structural interface between T-cell receptors and peptide-MHC complexes, identifying critical binding residues to predict activation potency.

Intelligent Nano-Vaccine Carrier Optimizer

Tailored for bio-nanotechnology research, this platform simulates the synergy between specialized antigens and delivery vehicles (LNPs, protein polymers) to maximize in vivo stability.

Research Insight: The Role of AI in Designing Functional Nanovaccines

Lessons from SARS-CoV-2 and Application to Tumor Neoantigens

The emergence of AI and computational modeling has revolutionized vaccine design. According to recent literature (e.g., Vaccines 2024, 12, 764), functionally designed nanovaccines utilizing AI-aided "in silico" process modeling can significantly redefine benchmarks for stability and efficacy. While the study focused on SARS-CoV-2, the principles of AI-aided analysis are directly applicable to tumor neoantigen research:

Precision Engineering: AI-aided modeling allows for the crafting of vaccine components that fine-tune antigen presentation and immunomodulation, ensuring the therapeutic agent is delivered exactly where needed.
Optimized Nano-Delivery: In nanovaccine design, AI tools help predict the interaction between antigens (like neoepitopes) and various carriers (lipid nanoparticles, protein-based nanoparticles, etc.), maximizing the natural immunity response.
Rapid Iteration: The integration of AI drastically reduces the time and expenses involved in candidate selection, enabling researchers to react to emerging viral variants or highly heterogeneous tumor mutanomes with unprecedented speed.
Personalized Profiling: By understanding unique immune profiles through AI analysis, vaccinations can be tailored to trigger the best possible protective immune response, as seen in advanced cancer immunotherapy strategies.

Functionalized lipid components of LNP nanovaccines.

Fig.1 Functional modification of lipid constituents in LNP nanovaccines..^1,2

FAQs About Our AI-Aided Analysis Platform

Traditional algorithms often only look at binding affinity. Our AI-aided analysis technology platform integrates proteasomal cleavage, TAP transport, and TCR recognition probability, providing a more biological and accurate immunogenicity score for preclinical candidates.

Yes. Our neural networks are trained on cross-reactive binding patterns, allowing for high-accuracy predictions even for less common HLA alleles frequently encountered in global research populations.

Depending on the depth of the sequencing data, our AI-aided analysis technology platform can complete a full prioritized ranking of neoantigens within 5-10 business days, allowing you to proceed quickly to experimental validation.

Absolutely. We use AI to optimize the order of epitopes in a multi-epitope string and design linkers that maximize the processing and presentation of each individual neoantigen in your preclinical constructs.

We offer a range of preclinical in vitro immunogenicity services, such as ELISpot, flow cytometry, and in vivo efficacy studies in animal models to confirm that the AI-predicted targets elicit the expected anti-tumor immune responses.